Nebivolol: Nursing Drug Guide, Bradycardia & Hold Rules
Once-daily beta-1 blocker for hypertension with vasodilatory activity: the bedside priority is apical pulse and blood pressure before every dose—symptomatic bradycardia, hypotension, and heart block can develop or worsen, especially with nodal drugs or CYP2D6 inhibitors on the MAR, and abrupt withdrawal in coronary artery disease can trigger severe angina, myocardial infarction, or ventricular arrhythmias.
Nebivolol blocks beta-1 receptors and promotes nitric oxide-mediated vasodilation per labeling, lowering heart rate and blood pressure. The worst realistic failures are symptomatic bradycardia, hypotension, and AV block—especially with digoxin, diltiazem, or verapamil on the MAR—and duplicate beta-blocker exposure or excessive levels when CYP2D6 inhibitors such as fluoxetine are co-prescribed. In coronary artery disease, abrupt discontinuation can precipitate severe angina, myocardial infarction, or ventricular arrhythmias. Nurses must measure apical pulse for a full minute and blood pressure before each dose, hold when parameters are out of range, and never stop or skip doses without prescriber-directed tapering.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Count apical pulse for a full minute and check blood pressure before every nebivolol dose. Hold when heart rate or blood pressure fall below prescriber or protocol limits, screen for duplicate beta blockers and CYP2D6 inhibitors, and use 2.5 mg starting doses in severe renal or moderate hepatic impairment per labeling. Never stop abruptly in coronary artery disease—taper per prescriber guidance.
Most common brand names
Bystolic is the primary U.S. brand for nebivolol. Multiple generic manufacturers supply nebivolol tablets; repackaged labels in DailyMed have listed misspellings such as nebibolol—verify the generic name on every label and MAR.
Confirm strength (2.5, 5, 10, or 20 mg), once-daily schedule, and that the patient is not receiving a second beta blocker from another prescriber or home medication list.
| Product | Formulation | Nursing verification |
|---|---|---|
| Bystolic | Oral tablets 2.5, 5, 10, 20 mg; once daily | Triangular tablets engraved with FL and strength; swallow whole |
| Generic nebivolol | Same strengths; once daily per order | Read full generic name—confusable with other -olol agents |
| Combination products | Not specified in the reviewed prescribing information as fixed-dose combinations with nebivolol | Screen home and inpatient lists for separate antihypertensives that duplicate beta blockade |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Nebivolol is a beta-1 adrenergic blocking agent indicated for the treatment of hypertension to lower blood pressure per FDA labeling. It may be used alone or with other antihypertensive agents. It is not approved for use in pediatric patients under 18 years of age.
| Use | Detail |
|---|---|
| Hypertension | Once-daily oral therapy; lowering blood pressure reduces risk of fatal and nonfatal cardiovascular events, primarily stroke and MI, per class labeling context |
| Combination therapy | May be combined with diuretics, ACE inhibitors, ARBs, or calcium channel blockers per prescriber order—verify for duplicate beta blockade |
| Off-label uses | Not specified in the reviewed prescribing information beyond hypertension |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Nebivolol is a racemic mixture: d-nebivolol provides beta-1 blockade and l-nebivolol contributes to vasodilation through nitric oxide release per labeling. The antihypertensive effect involves decreased heart rate, reduced myocardial contractility, diminished sympathetic outflow, reduced renin activity, and decreased peripheral vascular resistance.
| Physiologic effect | Clinical result | Nursing implication |
|---|---|---|
| Beta-1 blockade | Bradycardia, reduced contractility | Full-minute apical pulse before every dose |
| Nitric oxide vasodilation | Peripheral vasodilation; may blunt pure chronotropic effects | Still monitor BP and pulse—do not assume immunity to bradycardia |
| Reduced renin | Lower blood pressure over days to weeks | Expect gradual BP response during up-titration every 2 weeks |
| AV nodal effects | Heart block risk with nodal drugs | Hold for new block; review digoxin and non-dihydropyridine CCB orders |
| CYP2D6 metabolism | Higher exposure in poor metabolizers; raised levels with inhibitors | Screen fluoxetine, paroxetine, quinidine, propafenone on MAR |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Dosing must be verified against current prescribing information, prescriber order, renal and hepatic function, and local policy. Nebivolol is taken once daily with or without food.
| Scenario | Typical approach (labeling summary) | Nursing note |
|---|---|---|
| Hypertension titration | Start 5 mg once daily; increase every 2 weeks to max 40 mg | More frequent dosing unlikely to be beneficial per labeling |
| Severe renal impairment (ClCr <30) | Initial 2.5 mg once daily; titrate slowly | Not studied in dialysis—consult nephrology and pharmacy |
| Moderate hepatic impairment | Initial 2.5 mg once daily; titrate slowly | Severe hepatic impairment (Child-Pugh >B) is contraindicated |
| CYP2D6 poor metabolizers | No dose adjustment required per labeling | Still monitor for excessive bradycardia if inhibitors added |
| Pediatric | Not approved under 18 years | Do not administer off-label without explicit prescriber and policy approval |
| Maximum dose | 40 mg once daily for hypertension | Verify MAR if dose above 20 mg—confirm intentional titration |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information for a single missed dose. Do not double doses. Contact prescriber or pharmacist if multiple doses are missed, especially in coronary artery disease, because abrupt interruption increases ischemic risk.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (antihypertensive) | Not specified in the reviewed prescribing information as a single numeric value | Expect gradual blood pressure lowering during up-titration at 2-week intervals |
| Peak plasma (d-nebivolol) | About 1.5–4 hours after oral dosing per labeling | Assess vitals across the shift—not only at one fixed time |
| Duration | Once-daily dosing provides 24-hour coverage per labeling | Missed doses and abrupt stops still carry CAD withdrawal risk—clarify taper |
| Half-life (d-nebivolol) | About 12 hours in CYP2D6 extensive metabolizers; about 19 hours in poor metabolizers | Poor metabolizers and CYP2D6 inhibitors may prolong effect—watch bradycardia |
| Metabolism / excretion | Glucuronidation and CYP2D6 oxidation; renal and hepatic routes per labeling | Lower starting dose in severe renal or moderate hepatic impairment; trend basic metabolic panel when clinically indicated |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Apical pulse for a full minute and blood pressure (supine and standing when orthostasis is a concern)
- 12-lead ECG or rhythm strip if history of heart block, syncope, or new palpitations
- Renal function (creatinine, estimated clearance) for dose limits
- Perform medication reconciliation for other beta blockers, calcium channel blockers, and nodal agents
Contraindications
- Severe bradycardia; heart block greater than first degree; sick sinus syndrome without permanent pacemaker; cardiogenic shock; decompensated cardiac failure per labeling
- Severe hepatic impairment (Child-Pugh >B)—not recommended per labeling
- Known hypersensitivity to nebivolol or any formulation component
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Additive slowing of AV conduction; bradycardia risk | Monitor pulse and rhythm closely; hold per parameters and notify prescriber for new bradyarrhythmia |
| Diltiazem / verapamil | Increased risk of bradycardia and heart block | Verify orders; trend vitals; escalate symptomatic hypotension or block |
| Insulin / oral hypoglycemics | May mask hypoglycemia symptoms (tachycardia, tremor) in type 2 diabetes | Teach glucose monitoring; do not rely on adrenergic warning signs alone |
| Fluoxetine / paroxetine (CYP2D6 inhibitors) | Increased nebivolol exposure; bradycardia risk | Notify prescriber/pharmacist; monitor pulse closely; dose reduction may be needed per labeling |
| Sympathomimetics (e.g., epinephrine for anaphylaxis) | High beta-1 blockade may blunt bronchodilator response; unopposed alpha effects possible | Document beta-blocker use; follow anaphylaxis protocol and prescriber guidance |
On a small screen, swipe or scroll sideways to see the full table.
Asthma / reactive airways: Although nebivolol is cardioselective, use caution in patients with asthma or bronchospastic disease; bronchospasm can occur, especially at higher doses or if selectivity is lost.
Perioperative and anesthesia considerations
Chronic beta-blocker therapy should not be stopped abruptly before noncardiac surgery per many guidelines, but the anesthesiologist and surgeon must know the patient takes nebivolol. Unopposed alpha stimulation if epinephrine is required is a team concern—document beta-blocker use on preoperative checklists.
Beta-blocker withdrawal has been associated with increased risk of MI and chest pain in patients with coronary artery disease per labeling. When nebivolol is discontinued, taper gradually per prescriber guidance and monitor for increased angina, arrhythmias, or blood pressure rebound. Nurses should clarify taper orders on discharge and teach patients not to run out of medication without a refill plan.
Administration
Route: Oral tablets only—2.5, 5, 10, and 20 mg strengths per labeling. Not applicable to IV or other routes in the reviewed prescribing information.
- Once daily at the same time each day, with or without food per labeling
- Swallow tablets whole—triangular Bystolic tablets are unscored; consult pharmacy before crushing or splitting
- Verify strength on MAR matches dispensed product (2.5 vs 5 vs 10 vs 20 mg)
- During up-titration, increases occur at 2-week intervals per prescriber order—not more frequent dosing
- Bedside identification: read full generic name nebivolol—not another -olol beta blocker
| Administration step | Action |
|---|---|
| Before dose | Apical pulse (60 seconds), blood pressure, compare to hold parameters, review MAR for duplicate beta blockers |
| During pass | Right patient, drug, dose, route, time; educate if pulse is borderline |
| After dose | Reassess orthostatic symptoms if hypotension risk; document hold or administration with vital signs |
| Discharge | Teach taper if discontinuing; provide refill plan; warn against stopping when BP improves |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- Gradual reduction in resting heart rate and blood pressure toward prescriber targets over days to weeks
- Headache and fatigue may occur early—distinguish expected adjustment from symptomatic bradycardia or hypotension
- Patient reports improved blood pressure readings without presyncope—if dizziness or fatigue worsen after dose increase, reassess hold parameters and notify prescriber
Red flags — Stop and act
Bradycardia and conduction delay can progress to hemodynamic collapse. Abrupt withdrawal in ischemic heart disease is equally dangerous.
- Heart rate below prescriber hold limit, new second- or third-degree AV block, or pauses on monitor
- Symptomatic hypotension, syncope, or cold clammy extremities after dose
- Wheezing or bronchospasm in reactive airway disease—hold and escalate respiratory pathway
- Rest angina, crushing chest pain, or diaphoresis after missed doses or self-discontinuation—treat as acute coronary syndrome per protocol
- Signs of heart failure decompensation (crackles, weight gain, orthopnea) in patients with reduced ejection fraction
- Depression, confusion, or nightmares newly reported after dose increase—notify prescriber for mental status review
- Peripheral cyanosis or pain in fingers/toes suggesting severe beta-blockade—urgent perfusion assessment
Adverse effects
| Adverse effect | Frequency / notes | Nursing response |
|---|---|---|
| Bradycardia | Common; dose-related | Hold dose, notify prescriber, obtain rhythm strip; prepare for pacing pathway if symptomatic |
| Hypotension / dizziness | Common early in therapy or after dose increase | Assist with position changes; hold per parameters; monitor orthostatics |
| Headache / diarrhea | Common in hypertension trials (≥1% and greater than placebo) per labeling | Supportive care; notify prescriber if severe or persistent |
| Fatigue / dizziness | Common per labeling | Assess orthostatics; hold if symptomatic hypotension or bradycardia |
| Bronchospasm | Reported postmarketing; cardioselective but not absolute protection | Hold drug; bronchodilator therapy per prescriber; document intolerance |
| Masked hypoglycemia symptoms | Class effect in diabetes | Emphasize glucose checks; educate on sweating and confusion as alternate cues |
| Peripheral coldness / Raynaud symptoms | Class effect | Assess extremity perfusion; notify prescriber if painful or cyanotic |
| Sleep disturbance / vivid dreams | Central nervous system effect reported with beta blockers | Assess timing of dose; notify prescriber if distressing or persistent |
| Peripheral edema | Reported at low rates in trials per labeling | Assess volume status; notify prescriber if rapid weight gain or dyspnea |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Nebivolol overdose most commonly presents with bradycardia and hypotension per labeling; cardiac failure, dizziness, hypoglycemia, fatigue, and vomiting may also occur. No single specific antidote is listed in the reviewed prescribing information—management is supportive.
Management per labeling
- Stop nebivolol; provide general supportive and symptomatic treatment
- Bradycardia: IV atropine; if inadequate, isoproterenol or cautious positive chronotrope; transvenous pacing if necessary
- Hypotension: IV fluids and vasopressors; IV glucagon may be useful per labeling
- Heart failure: digitalis glycoside and diuretics; inotropic and vasodilating agents per prescriber
- Bronchospasm: bronchodilators per protocol
- Hypoglycemia: IV glucose; repeat glucose or glucagon as needed
- Half-life at low doses about 12–19 hours—supportive care until clinical stability
| Overdose manifestation | Intervention (labeling summary) |
|---|---|
| Severe bradycardia / AV block | Atropine; pacing or isoproterenol if refractory |
| Hypotension | IV fluids; vasopressors; glucagon per protocol |
| Bronchospasm | Bronchodilators per protocol |
| Hypoglycemia | IV glucose; glucagon if needed |
| Drug removal | Not specified in the reviewed prescribing information as a primary elimination strategy |
On a small screen, swipe or scroll sideways to see the full table.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Nebivolol vs metoprolol / atenolol / carvedilol—all end in “-olol”; read full generic name on label and MAR
- Bystolic vs generic spelling—DailyMed repackaged labels have listed “nebibolol” misspellings—verify name on every label
- Multiple beta blockers—duplicate therapy from inpatient and home lists
- Strength errors—2.5, 5, 10, and 20 mg tablets; do not confuse with 5 mg look-alike from another -olol drug
- Once-daily assumption—do not give twice daily unless a new prescriber order explicitly changes schedule
- Abrupt stop—patient may confuse hold for stop; document taper orders clearly
No specific look-alike/sound-alike pair was identified in the reviewed sources beyond general beta-blocker name similarity, but standard medication-name verification still applies.
High-risk populations
| Population | Considerations |
|---|---|
| Coronary artery disease | Never discontinue abruptly; taper gradually—withdrawal may increase MI and chest pain per labeling |
| Older adults | No dose adjustment required per labeling; still higher fall risk with dizziness and hypotension |
| Severe renal impairment (ClCr <30) | Start 2.5 mg once daily; titrate slowly; not studied in dialysis |
| Moderate hepatic impairment | Start 2.5 mg once daily; titrate slowly per labeling |
| Severe hepatic impairment | Contraindicated (Child-Pugh >B) per labeling |
| Diabetes mellitus | Masks hypoglycemia tachycardia; monitor glucose closely |
| Reactive airway disease | Use caution; bronchospasm possible despite cardioselectivity |
| Pregnancy | Use only if potential benefit justifies fetal risk per labeling; animal data showed fetal toxicity at high doses |
| Lactation | Not recommended during nursing—beta blockers may cause serious adverse reactions in nursing infants, especially bradycardia per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Apical pulse (full minute), blood pressure, and rhythm before each dose and when symptoms change
- Orthostatic vital signs after dose increases or in fall-risk patients
- Signs of heart failure decompensation if patient has reduced ejection fraction (weight, edema, crackles, dyspnea)
- Blood glucose trends in diabetes; angina frequency and exertional symptoms in CAD
Document
- Heart rate, blood pressure, and whether dose was held with prescriber notification
- Taper plan when discontinuing; patient education on not stopping abruptly
- Any bronchospasm, syncope, or angina after missed doses
| Parameter | Typical nursing frequency | Action threshold (verify local protocol) |
|---|---|---|
| Apical pulse | Before each dose; when symptoms change | Hold and notify if below prescriber minimum (often <60/min in adults) |
| Blood pressure | Before each dose; orthostatics after dose changes | Hold for symptomatic hypotension or SBP below protocol limit |
| Rhythm | When pulse irregular or patient reports palpitations | Obtain ECG or rhythm strip; hold for new AV block |
| Liver function | When hepatic disease or rising transaminases | Lower initial dose; slow titration; watch for excessive bradycardia |
| Blood glucose | Per diabetes plan when on insulin or sulfonylureas | Teach alternate hypoglycemia cues when beta blocker masks tachycardia |
| Angina symptoms | Each shift in CAD; after missed doses | Escalate rest angina or increasing frequency—possible withdrawal or undertreatment |
On a small screen, swipe or scroll sideways to see the full table.
Patient teaching
- Take at the same time daily; do not double doses if one is missed—call the clinic for guidance
- Never stop suddenly if you have heart disease or angina; prescriber will taper the dose
- Check pulse before taking if instructed; report heart rate below your prescriber limit, fainting, or new wheezing
- Rise slowly from sitting or lying down to reduce dizziness
- If you have diabetes, monitor blood glucose as directed—this medicine can hide shaking and fast heartbeat during low sugar
- Inform all clinicians and dentists that you take a beta blocker before procedures requiring epinephrine or certain anesthetics
| Teach-back topic | Patient should be able to say |
|---|---|
| Pulse check | How to count pulse for one minute and when to call if too slow |
| Missed doses | Do not double; call clinic if several doses missed |
| Stopping therapy | Prescriber must taper—never stop suddenly if heart disease |
| Diabetes | Sweating or confusion may still occur; check glucose as directed |
| When to seek care | Fainting, severe dizziness, chest pain, new wheezing |
On a small screen, swipe or scroll sideways to see the full table.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Apical pulse below prescriber or protocol minimum (commonly <60 beats/min in adults—verify institutional parameters)
- Systolic blood pressure below hold threshold or symptomatic hypotension
- New second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia on monitor
- Active bronchospasm or severe reactive airway exacerbation
- Patient self-discontinued or multiple doses missed in CAD—do not restart full dose without prescriber/pharmacy plan
- Duplicate beta blocker on MAR and home list, or CYP2D6 inhibitor added without dose review
- Severe hepatic impairment or contraindicated heart block present
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
| Common institutional hold example | Nursing action |
|---|---|
| Apical pulse <60/min | Hold dose; notify prescriber; recheck in 30–60 minutes per protocol |
| SBP <100 mmHg or symptomatic low BP | Hold; orthostatic assessment; notify prescriber |
| New heart block or irregular pulse | Hold; obtain rhythm strip; urgent notification |
| Active wheeze / bronchospasm | Hold; treat respiratory symptoms; notify prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pulse check | Apical count full 60 seconds—radial pulse may be irregular or weak with block |
| Timing | Once daily at same clock time; food optional per labeling |
| Renal/hepatic start | 2.5 mg initial dose when ClCr <30 or moderate hepatic impairment |
| Perioperative | Continue or hold per anesthesia/prescriber plan—abrupt withdrawal risky in CAD |
| Commonly missed | Second beta blocker on home list; fluoxetine/paroxetine raising levels; patient stops drug when BP looks normal |
| Ask pharmacy when | CYP2D6 inhibitor interaction, renal/hepatic dose, enteral tube administration, or taper in CAD |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Nebivolol is a once-daily oral antihypertensive whose safety hinges on vital signs before administration, renal/hepatic dose limits, and disciplined tapering at discontinuation.
1. Check-before-you-give protocol
- Right patient, drug, dose (2.5–40 mg), route, time—and right apical pulse and blood pressure
- Compare heart rate to hold parameters on the MAR and nursing protocol
- Screen for duplicate beta-blocker therapy and CYP2D6 inhibitors on MAR and home med list
- Confirm 2.5 mg start when severe renal or moderate hepatic impairment is documented
2. High-alert and safety badge
Not an ISMP high-alert medication, but bradycardia and withdrawal ischemia require the same vital-sign disciplineTreat pre-dose pulse and blood pressure checks as non-negotiable even when the drug is not on your facility high-alert list.
3. Clinical workflow: hold and question rules
- If pulse or blood pressure is below threshold, hold and notify before giving—do not administer and document later
- If two beta blockers appear on the MAR or home list, stop and reconcile with pharmacy before the next dose
- If the patient skipped several doses, clarify restart vs taper with pharmacy—especially post-MI or angina
- Before surgery, confirm perioperative beta-blocker plan with anesthesia and cardiology
4. Critical teach-back questions
- “What should you do if your pulse is too slow before your pill?” (Hold and call prescriber/clinic per instructions—do not take the dose.)
- “Can you stop this medicine when your blood pressure looks good?” (No—prescriber must taper; sudden stop can cause chest pain or heart attack in heart disease.)
5. Care coordination
Pharmacist: Renal dosing, interaction review with digoxin and calcium channel blockers, taper schedules
Prescriber / cardiology: Symptomatic bradycardia, heart block, failed angina control, or perioperative beta-blocker decisions
🧠 Quick mental checklist
- Correct nebivolol strength and once-daily schedule on this MAR?
- Apical pulse for full minute and BP before this dose?
- Below hold heart rate or blood pressure?
- Any nodal drugs (digoxin, diltiazem) increasing block risk?
- Any CYP2D6 inhibitor (fluoxetine, paroxetine) that could raise nebivolol levels?
- If stopping therapy, is there a taper—not abrupt discontinuation?
Nebivolol NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for nebivolol with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, select-all-that-apply cues, deterioration trends, matrix urgency sorting, withdrawal judgment, and overdose cloze—recognise bradycardia and duplicate beta-blocker exposure → analyse CYP2D6 and nodal-drug interactions → prioritise holds → act → evaluate outcomes after each intervention.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nebivolol (Bystolic) 10 mg PO daily — due 0800; held yesterday for HR 52
- Fluoxetine 20 mg PO daily — given 0700 (new this admission)
- Digoxin 0.125 mg PO daily — given 0700
- Lisinopril 10 mg PO daily — given 0700
- Creatinine 1.8 mg/dL; eGFR estimated 38 mL/min — nebivolol started at 2.5 mg on admission, increased to 10 mg last week per prescriber
- AST 42 U/L; ALT 38 U/L — moderate hepatic impairment documented; Child-Pugh B
- Potassium 4.1 mEq/L; glucose 142 mg/dL fasting
- Apical pulse 56/min regular; BP 112/68 supine; BP 98/62 standing
- SpO2 96% on room air; denies chest pain; reports lightheadedness when standing
- Hold parameters on chart: give if apical pulse ≥60 and SBP ≥100
- History: hypertension, type 2 diabetes, stable angina; no pacemaker
- 0700: Home list includes metoprolol 25 mg BID—patient states they still take it some mornings; bradycardia noted on prior shift
- 0730: Asks to skip nebivolol because BP is “good”; stopped all heart pills for 2 days last month and had worsening chest pressure
Answer key & rationale
Frequently asked questions
Common nursing questions about nebivolol focus on pre-dose pulse and blood pressure checks, renal and hepatic dose limits, hold parameters, CYP2D6 interactions, safe tapering, and overdose management when no single antidote exists.
What should I check before giving nebivolol?
Count apical pulse for a full minute and obtain blood pressure (orthostatic when indicated). Confirm dose and strength (2.5, 5, 10, or 20 mg) and once-daily schedule. Review hold parameters, screen for duplicate beta blockers, digoxin, calcium channel blockers, and CYP2D6 inhibitors, and verify renal/hepatic dose limits. Document findings before administration.
When should a nurse hold nebivolol?
Hold when apical pulse or blood pressure falls below prescriber or protocol limits, when new heart block greater than first degree or symptomatic bradycardia is present, during active bronchospasm, when duplicate beta-blocker therapy is suspected, or when multiple doses were missed in coronary artery disease—do not restart full dose without prescriber/pharmacy guidance.
Why does renal or hepatic impairment change the starting dose?
Labeling recommends an initial dose of 2.5 mg once daily in severe renal impairment (ClCr less than 30 mL/min) and in moderate hepatic impairment, with slow titration if needed. Severe hepatic impairment (Child-Pugh greater than B) is contraindicated.
Can nebivolol be stopped suddenly?
No. Beta-blocker withdrawal in coronary artery disease can increase risk of myocardial infarction and chest pain per labeling. Taper gradually with monitoring per prescriber guidance—even patients treated only for hypertension should not stop abruptly without a plan.
What adverse effects matter most with nebivolol?
Bradycardia, headache, fatigue, dizziness, and diarrhea were common in trials. Serious concerns include symptomatic bradycardia, hypotension, AV block, bronchospasm, masked hypoglycemia symptoms in diabetes, and angina or MI after abrupt withdrawal in coronary artery disease.
Does fluoxetine interact with nebivolol?
Yes. Fluoxetine is a CYP2D6 inhibitor that can substantially increase nebivolol exposure per labeling. Monitor pulse and blood pressure closely and notify the prescriber or pharmacist—dose reduction may be needed.
References
-
U.S. National Library of Medicine. BYSTOLIC (nebivolol) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=673f5ad2-c09b-4a89-9407-efdadd007917
-
Drugs and Lactation Database (LactMed). Nebivolol. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK570553/
-
American Heart Association. Types of blood pressure medications — Beta blockers.https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
-
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline NG136.https://www.nice.org.uk/guidance/ng136
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.
Last content review: May 29, 2026.